Idelalisib and rituximab in relapsed chronic lymphocytic leukemia Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Purines
  • Quinazolinones

abstract

  • The combination of idelalisib and rituximab, as compared with placebo and rituximab, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy. (Funded by Gilead; ClinicalTrials.gov number, NCT01539512.).

publication date

  • March 17, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4161365

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1315226

PubMed ID

  • 24450857

Additional Document Info

start page

  • 997

end page

  • 1007

volume

  • 370

number

  • 11